0000000000464022

AUTHOR

Vatrella A.

showing 2 related works from this author

Early management of COPD: Where are we now and where do we go from here? a delphi consensus project

2019

Fabiano Di Marco,1 Piero Balbo,2 Francesco de Blasio,3 Vittorio Cardaci,4 Nunzio Crimi,5 Giuseppe Girbino,6 Girolamo Pelaia,7 Pietro Pirina,8 Pietro Roversi,9 Pierachille Santus,10,11 Nicola Scichilone,12 Alessandro Vatrella,13 Patrizio Pasqualetti,14 Mauro Carone15 1Department of Health Sciences, University of Milan, Respiratory Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2SC Malattie dell’Apparato Respiratorio, AOU Maggiore della Carità, Novara, Italy; 3Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center S.p.A. Private Hospital, Department of Medicine and Health Sciences “V Tiberio”, University of Molise, Campobasso, It…

Adrenergic beta-2 Receptor AgonistPulmonary and Respiratory Medicinedrug combinationspractice guidelines as topicConsensuPredictive Value of Testbronchodilator therapy; dyspnea; italy; respiratory symptoms; adrenal cortex hormones; adrenergic beta-2 receptor agonists; adult; bronchodilator agents; consensus; delphi technique; drug combinations; early diagnosis; early medical intervention; evidence-based medicine; female; humans; italy; male; middle aged; muscarinic antagonists; practice guidelines as topic; predictive value of tests; pulmonary disease; chronic obstructive; surveys and questionnaires; treatment outcomeadrenal cortex hormonesSettore MED/10 - Malattie Dell'Apparato RespiratorioInternational Journal of Chronic Obstructive Pulmonary DiseasedyspnoeaAdrenal Cortex HormonePulmonary Disease Chronic ObstructivemaleDrug CombinationEarly Diagnosiitalymiddle agedSurveys and Questionnairehumansmuscarinic antagonistsBronchodilator AgentOriginal Researchearly medical interventionpulmonary diseaselcsh:RC705-779chronic obstructiveHealth Policyadultbronchodilator agentsEnvironmental and Occupational Healthrespiratory symptomsbronchodilator therapylcsh:Diseases of the respiratory systemdyspneaBronchodilator therapy; Dyspnea; Italy; Respiratory symptoms; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational Healthpredictive value of testsMuscarinic AntagonistfemaleconsensusRespiratory symptomsurveys and questionnairestreatment outcomePublic Healthdelphi techniqueadrenergic beta-2 receptor agonistsevidence-based medicineHumanearly diagnosis
researchProduct

MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

2018

mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly affect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), th…

AllergyHEALTH-ORGANIZATIONIMPACTRespiratory Medicine and Allergy[SDV]Life Sciences [q-bio]Allergic Rhinitis and its Impact on Asthma - ARIAReviewMASK - Mobile Airways Sentinel networK0302 clinical medicine610 Medical sciences MedicineApp; ARIA; Asthma; Care pathways; MASK; mHealth; Rhinitis; Immunology and Allergy; Immunology; Pulmonary and Respiratory MedicineHealth careMedicine and Health SciencesImmunology and Allergy030212 general & internal medicineAndroid (operating system)mHealthRinitisRhinitiComputingMilieux_MISCELLANEOUSLungmedicin och allergiRhinitisPRODUCTIVITY3. Good healthALLERGIC RHINITISmHealthRiniteCare pathwaysMedical emergencyLife Sciences & BiomedicinePulmonary and Respiratory MedicineSTRATEGIESMASKMASK study groupImmunologyMEDLINE610K-ANONYMITYPharmacy[object Object]Settore MED/10 - Malattie Dell'Apparato RespiratorioVALIDATIONMACVIA-ARIA03 medical and health sciencesmedicineMobile technologyTECHNOLOGYApp -MASKApp ; ARIA ; Asthma ; Care pathways ; MASK ; mHealth ; RhinitisARIA; App; Asthma; Care pathways; MASK; Rhinitis; mHealthAsmaAsthmaCare pathwayScience & TechnologyARIAbusiness.industryApp; ARIA; Asthma; Care pathways; MASK; mHealth; RhinitisSettore MED/09 - MEDICINA INTERNACorrectionGuidelineRC581-607medicine.diseaseAsthma030228 respiratory systemImmunologic diseases. AllergybusinessAppEUROPEAN COUNTRIES[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct